曲美他嗪对慢性收缩性心力衰竭患者炎症因子的影响

Effect of trimetazidine on levels of inflammatory factors in patients with chronic systolic heart failure

目的:探讨曲美他嗪对慢性收缩性心力衰竭患者炎症因子的影响。方法:148例收缩性心力衰竭患者随机分为曲美他嗪组及对照组,各74例。对照组予以心力衰竭的常规治疗,曲美他嗪组在常规治疗基础上加用曲美他嗪,治疗6个月后观察两组的症状及心功能的改善情况。检测两组患者入组时及治疗6个月后LVED和LVEF,血浆BNP、IL-1、IL-6、TNF-α、CRP水平。结果:治疗6个月后,曲美他嗪组症状改善的显效率显著高于对照组(P <0. 05),心脏彩超示曲美他嗪组LVED及LVEF均较入组时显著改善(P <0. 05)),且血浆BNP、IL-1、IL-6、TNF-α、CRP水平均较入组时和对照组显著降低(P <0. 05或P <0. 01)。结论:慢性收缩性心力衰竭患者常规治疗基础上加用曲美他嗪可进一步缓解临床症状、改善心功能、降低BNP及IL-1、IL-6、TNF-α、CRP水平。

Objective：To investigate the effect of trimetazidine on levels of inflammatory factors in patients with chronic systolic heart failure（CSHF）.Methods：148 CSHF patients were randomly divided into trimetazidine group and control group, 74 cases in each group. The control group was given routine treatment for heart failure, and the trimetazidine group was given trimetazidine on the basis of routine treatment. After 6-month treatment, the symptoms and cardiac function of the two groups were observed. The levels of LVED, LVEF, BNP, IL-1, IL-6, TNF-α and CRP were measured at the time of admission and 6 months after treatment.Results：After 6-month treatment, the symptoms of trimetazidine group were significantly improved （ P 〈0.05）; color Doppler ultrasound showed that LVED and LVEF of the trimetazidine group were significantly improved compared with those at the time of admission（ P 〈0.05）; plasma BNP, IL-1, IL-6, TNF-α and CRP levels were significantly lower than those at the time of admission and those of the control group （ P 〈0.05 or P 〈0.01）.Conclusion：Trimetazidine can further relieve clinical symptoms, improve cardiac function, decrease BNP, IL-1, IL-6, TNF-αand CRP levels in CSHF patients on the basis of routine treatment.